Intermedin Alleviates Renal Ischemia-Reperfusion Injury and Enhances Neovascularization in Wistar Rats.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Auckland, N.Z.] : Dove Press Limited
    • Subject Terms:
      Adrenomedullin/*metabolism ; Endothelin-1/*metabolism ; Matrix Metalloproteinase 2/*metabolism ; Matrix Metalloproteinase 9/*metabolism ; Neovascularization, Pathologic/*metabolism ; Neuropeptides/*metabolism ; Reperfusion Injury/*metabolism; Adrenomedullin/administration & dosage ; Adrenomedullin/genetics ; Animals ; Male ; Neuropeptides/administration & dosage ; Neuropeptides/genetics ; Rats ; Rats, Wistar ; Ultrasonic Waves
    • Abstract:
      Background: Ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury (AKI) and increases the risk of subsequently developing chronic kidney disease. Angiogenesis has been shown to play an important role in reducing renal injury after ischemia reperfusion. In this study, we investigated whether IMD could reduce renal IRI by promoting angiogenesis.
      Methods: The kidneys of Wistar rats were subjected to 45 min of warm ischemia followed by 24 h of reperfusion. IMD was overexpressed in vivo using the vector pcDNA3.1-IMD transfected by an ultrasound-mediated system. The renal injury after ischemia reperfusion was assessed by detection of the serum creatinine concentration and histologic examinations of renal tissues stained by PAS and H&E. Real-time PCR and Western blotting were used to determine the mRNA and protein levels, respectively. Histological examinations were used to assess the expression of CD31, MMP2, MMP9, ET-1, VEGF and VEGFR2 in tissues.
      Results: Renal function and renal histological damage were significantly ameliorated in IMD-transfected rats after ischemia reperfusion. Compared to the IRI, IMD significantly promoted angiogenesis. IMD also upregulated the protein and mRNA expression levels of VEGF and VEGFR2 and downregulated the expression level of MMP2, MMP9 and ET-1.
      Conclusion: IMD could protect the kidney after renal ischemia-reperfusion injury by promoting angiogenesis and reducing the destruction of the perivascular matrix.
      Competing Interests: The authors report no conflicts of interest in this work.
      (© 2020 Wang et al.)
    • References:
      Cancer Sci. 2018 Jan;109(1):132-140. (PMID: 29121426)
      Prog Urol. 2014 Jun;24 Suppl 1:S20-5. (PMID: 24950928)
      Contrib Nephrol. 2010;165:1-8. (PMID: 20427949)
      Drug Discov Today. 2011 Sep;16(17-18):762-78. (PMID: 21745586)
      Cardiovasc Res. 2010 Mar 1;85(4):864-73. (PMID: 19910445)
      Exp Ther Med. 2016 May;11(5):1573-1580. (PMID: 27168775)
      Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1040-7. (PMID: 19592612)
      Int J Nephrol. 2012;2012:505197. (PMID: 21826270)
      FEBS Lett. 2004 Jan 2;556(1-3):53-8. (PMID: 14706825)
      Lab Invest. 2011 Feb;91(2):170-80. (PMID: 20956976)
      Peptides. 2004 Oct;25(10):1643-56. (PMID: 15476931)
      J Mol Cell Cardiol. 2000 Feb;32(2):297-310. (PMID: 10722805)
      Nat Med. 2011 Nov 07;17(11):1391-401. (PMID: 22064429)
      J Pathol. 2003 Jul;200(4):423-8. (PMID: 12845610)
      Am J Physiol Renal Physiol. 2013 Jan 1;304(1):F112-9. (PMID: 23077098)
      Biochem Biophys Res Commun. 2012 Aug 24;425(2):443-9. (PMID: 22846580)
      Nephron Exp Nephrol. 2012;122(1-2):23-35. (PMID: 23548779)
      BMC Nephrol. 2015 Oct 23;16:169. (PMID: 26498843)
      Am J Transl Res. 2016 Oct 15;8(10):4289-4299. (PMID: 27830012)
      Cardiovasc Res. 2006 Feb 15;69(3):562-73. (PMID: 16405877)
      Cell Physiol Biochem. 2009;23(1-3):97-108. (PMID: 19255504)
      Kidney Int. 2004 Oct;66(4):1613-21. (PMID: 15458458)
      Nephrology (Carlton). 2013 Sep;18(9):623-32. (PMID: 23782291)
      Am J Nephrol. 2014;39(3):218-29. (PMID: 24603476)
      Biotech Histochem. 2014 May;89(4):304-14. (PMID: 24160412)
      Am J Physiol Renal Physiol. 2008 Apr;294(4):F928-36. (PMID: 18272597)
      J Clin Invest. 2011 Nov;121(11):4210-21. (PMID: 22045571)
      Nat Rev Cancer. 2008 Nov;8(11):865-73. (PMID: 18923434)
      Am J Physiol Renal Physiol. 2005 Jan;288(1):F91-7. (PMID: 15353401)
      Lancet. 1988 Nov 19;2(8621):1179-82. (PMID: 2903385)
      Kidney Int. 2007 Jul;72(2):151-6. (PMID: 17495858)
      Curr Protein Pept Sci. 2013 Jun;14(4):294-329. (PMID: 23745696)
      Am J Physiol Renal Physiol. 2004 May;286(5):F893-902. (PMID: 15075185)
      Nature. 1988 Mar 31;332(6163):411-5. (PMID: 2451132)
      J Biol Chem. 2004 Feb 20;279(8):7264-74. (PMID: 14615490)
    • Contributed Indexing:
      Keywords: ET-1; MMP2; MMP9; VEGF; VEGFR2; angiogenesis; intermedin; ischemia-reperfusion injury; kidney
    • Accession Number:
      0 (Adm2 protein, rat)
      0 (Endothelin-1)
      0 (Neuropeptides)
      148498-78-6 (Adrenomedullin)
      EC 3.4.24.24 (Matrix Metalloproteinase 2)
      EC 3.4.24.35 (Matrix Metalloproteinase 9)
    • Publication Date:
      Date Created: 20201118 Date Completed: 20210823 Latest Revision: 20220418
    • Publication Date:
      20231215
    • Accession Number:
      PMC7666991
    • Accession Number:
      10.2147/DDDT.S253019
    • Accession Number:
      33204068